Étiquette : santé mentale

Cannabis and Cannabinoids: Weighing the Benefits and Risks in Psychiatric Patients, Diana M. Martinez, MD Medscape .com, 2020

Cannabis and Cannabinoids: Weighing the Benefits and Risks in Psychiatric Patients Diana M. Martinez, MD Medscape .com, December 18, 2020 This transcript has been edited for clarity. Hello. I'm Diana Martinez. I'm a psychiatrist at the Columbia University Medical Center in the Department of Psychiatry. Today we'll be talking about the interaction between cannabis and psychiatric disorders. When I say "cannabis," this is really the same as marijuana. I use the term "cannabis" because this is a scientific term for the plant. I'm going to start with a brief history of cannabis. It’s been used for centuries in India as both an intoxicant and a [...]

Lire la suite

Bibliographie : Cannabis et Cannabinoides en Psychiatrie, Docteur Christian Sueur, GRECC, décembre 2020

Bibliographie : Cannabis et Cannabinoides en Psychiatrie   Docteur Christian Sueur, GRECC, décembre 2020. (4e version, décembre 2020....)   1 - Généralités : 1 - 11 2 -Cannabinoïdes et anxiété : 12 3 - Cannabidiol anxiolytique : 13 - 15 4 - Cannabidiol antipsychotique : 16 - 21 5 - Cannabinoïdes et dépression : 22 - 28 6 - Cannabidiol antidépresseur : 29 7 - Cannabinoïdes et Sommeil : 30 - 31 8 - Cannabinoïdes et addiction au Cannabis : 32 - 39 9 - Cannabinoïdes et addictions (cocaine, opiacés, amphétamines, alcool, tabac) : 40 - 54 10 - Cannabinoides et syndrome de Gilles de la Tourette : 58 - 59 11 - Cannabinoides et Hyperactivité [...]

Lire la suite

The potential synergistic effects between psychedelic administration and nature contact for the improvement of mental health, Sam Gandy et al, 2020

The potential synergistic effects between psychedelic administration and nature contact for the improvement of mental health Sam Gandy, Matthias Forstmann, Robin Lester Carhart-Harris, Christopher Timmermann, David Luke and Rosalind Watts Health Psychology Open, 2020, 1–21 Doi : 10.1177/2055102920978123   Abstract Therapeutic psychedelic administration and contact with nature have been associated with the same psychological mechanisms : decreased rumination and negative affect, enhanced psychological connectedness and mindfulness related capacities, and heightened states of awe and transcendent experiences, all processes linked to improvements in mental health amongst clinical and healthy populations. Nature-based settings can have inherently psychologically soothing properties which may complement all stages of psychedelic therapy (mainly [...]

Lire la suite

BIBLIOGRAPHIE : Substances Psychédéliques et Santé Mentale, Dr Christian SUEUR, GRECC, septembre 2020.

BIBLIOGRAPHIE : Substances Psychédéliques et Santé Mentale   Dr Christian SUEUR, GRECC, septembre 2020.     Psychédéliques : neurobiologie et psychopharmacologie : 1 - 3 Psychédéliques et réactions indésirables : 4 - 5 Psychédéliques et psychopathologie : 6 - 7 Psychédéliques et « psychoses induites » : 8 - 9 Psychédéliques et “Flash Backs” (Hallucinogen-Persisting Perception Disorders) : 10 - 11 Psychédéliques et « Bad trip » : 11 Psychédéliques et Réduction des risques : 12  

Lire la suite

Adverse Reactions to Psychedelic Drugs. A Review of the Literature, Rick J. STRASSMAN, 1984.

Adverse Reactions to Psychedelic Drugs. A Review of the Literature Rick J. STRASSMAN, M.D. THE JOURNAL OF NERVOUS AND MENTAL DISEASE, 1984, VOL. 172, NO. 10, 577-595. DOI : 10.1097/00005053-198410000-00001   The use of naturally occurring and synthetically derived compounds for their "psychedelic" effects has been a part of human culture for thousands of years. The basic pharmacology of the major synthetic psychedelic compounds primarily lysergic acid diethylamide [LSD]-25 is described and reference is made to their potentially beneficial psychological effects. Adverse reactions, defined as dysphoric and/or maladaptive/dysfunctional responses to the use of these drugs, sometimes require careful clinical judgment in order to diagnose. These reactions [...]

Lire la suite

Medicinal use of cannabis based products and cannabinoids, Tom P Freeman et al., 2019

Medicinal use of cannabis based products and cannabinoids Tom P. Freeman, Chandni Hindocha, Sebastian F. Green, Michael A. P. Bloomfield British Medical Journal, 2019, 365, l1141 doi : 10.1136/bmj.l1141   What you need to know • Cannabis based products for medicinal use contain cannabinoids derived from the cannabis plant, including Δ9-tetrahydrocannabinol (THC), cannabidiol (CBD), or a combination of THC and CBD. Synthetic cannabinoids for medicinal use typically mimic the effects of specific cannabinoids such as THC • THC is the constituent of cannabis that causes the “high,” whereas CBD is not intoxicating at typical doses. THC and CBD have contrasting mechanisms of action and therapeutic indications; THC [...]

Lire la suite

Short and Long-Term Effects of Cannabis on Symptoms of Post-Traumatic Stress Disorder, Emily M. LaFrance et al., 2020,

Short and Long-Term Effects of Cannabis on Symptoms of Post-Traumatic Stress Disorder Emily M. LaFrance, Nicholas C. Glodosky, Marcel Bonn-Miller, Carrie Cuttler Journal of Affective Disorders, 2020, 274, 298–304 Doi : 10.1016/j.jad.2020.05.132   A B S T R A C T Background : Many individuals use cannabis to manage symptoms of post-traumatic stress disorder (PTSD), and evidence indicates that the endocannabinoid system represents a viable target for treating these symptoms. Method : Data from 404 medical cannabis users who self-identified as having PTSD were obtained from Strainprint®, a medical cannabis app that patients use to track changes in symptoms as a function of different strains and doses [...]

Lire la suite

A Pilot Randomised Placebo-Controlled Trial of Cannabidiol to Reduce Severe Behavioural Problems in Children and Adolescents With Intellectual Disability, Daryl Efron et al., 2020

  A Pilot Randomised Placebo-Controlled Trial of Cannabidiol to Reduce Severe Behavioural Problems in Children and Adolescents With Intellectual Disability Daryl Efron, Jeremy L Freeman, Noel Cranswick, Jonathan M Payne, Melissa Mulraney, Chidambaram Prakash, Katherine J Lee, Kaitlyn Taylor, Katrina Williams British Journal of Clinical Pharmacology, 2020 Jun 1. doi : 10.1111/bcp.14399. Abstract Introduction : Severe Behavioural Problems (SBP) are a major contributor to morbidity in children with Intellectual Disability (ID). Medications used to treat SBP in ID are associated with a high risk of side effects. Cannabidiol has potential therapeutic effects in SBP. This pilot study aimed to investigate the feasibility of conducting a randomized placebo-controlled [...]

Lire la suite

Report et nouvelle date pour les 25ES Rencontres du RESPADD : Des drogues en santé mentale, 18 novembre 2020

Report et nouvelle date pour les 25ES Rencontres du RESPADD : Des drogues en santé mentale Affiche – 25es Rencontres RESPADD En raison de la situation sanitaire actuelle et pour préserver la santé de chacun, le RESPADD a décidé de reporter ses 25es Rencontres. NOUVELLE DATE : le 18 novembre 2020 Les 25es Rencontres professionnelles du RESPADD, réalisées en partenariat avec le Groupement addictions Franche-Comté, la Société psychédélique française et le CHS Saint-Ylie Jura, se tiendront le mercredi 18 novembre 2020 à la Commanderie de Dole. Cette nouvelle édition des Rencontres du RESPADD explorera les nouveaux usages des drogues en santé mentale et [...]

Lire la suite

High Times for Painful Blues : The Endocannabinoid System in Pain-Depression Comorbidity, Marie Fitzgibbon et al., 2016

High Times for Painful Blues : The Endocannabinoid System in Pain-Depression Comorbidity Marie Fitzgibbon, David P. Finn,  Michelle Roche International Journal of Neuropsychopharmacology, 2016, 19, (3), 1–20 doi : 10.1093/ijnp/pyv095   Abstract Depression and pain are two of the most debilitating disorders worldwide and have an estimate co-occurrence of up to 80%. Comorbidity of these disorders is more difficult to treat, associated with significant disability and impaired healthrelated quality of life than either condition alone, resulting in enormous social and economic cost. Several neural substrates have been identified as potential mediators in the association between depression and pain, including neuroanatomical reorganization, monoamine and neurotrophin depletion, dysregulation [...]

Lire la suite